alpha-aminopyridine has been researched along with Astrocytoma, Grade IV in 24 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 17 (70.83) | 24.3611 |
| 2020's | 7 (29.17) | 2.80 |
| Authors | Studies |
|---|---|
| Becker, KP; Burris, HA; Chowdhary, SA; Eakle, JF; Hainsworth, JD; Langdon, RM; Mekhail, T; Padula, GDA; Scarberry, M; Shaifer, CA; Shastry, M; Shih, K; West-Osterfield, K; Wright, D; Yost, KJ | 1 |
| Asthagiri, A; De Jong, J; Fadul, CE; Lewis, LD; Li, J; Loomba, J; Lopes, B; Miller, TW; Patel, SH; Purow, BW; Schiff, D; Traphagen, NA | 1 |
| Azaro, A; Balbin, OA; Cheng, Y; De Vos, F; Joerger, M; Kirsilae, T; Lassman, AB; Rodon, J; Sepulveda, J; Tabatabai, G; Tiedt, R; van den Bent, M; Vicente, S; Wen, PY; Wick, W; Yung, WKA; Zhang, H; Zhao, S | 1 |
| Beck, JT; DeGroot, J; Donnet, V; El-Hashimy, M; Mason, W; Mills, D; Rodon, JA; Rosenthal, M; Wen, PY | 1 |
| Campone, M; Chinot, O; Clement, PM; DeGroot, J; Donnet, V; El-Hashimy, M; Gan, H; Gil-Gil, MJ; Idbaih, A; Mason, W; Mills, D; Pineda, E; Raizer, J; Rosenthal, M; Wen, PY | 1 |
| Alshareef, M; Cachia, D; Das, A; Henderson, FC; Infinger, LK; Kanginakudru, I; Lindhorst, SM; Patel, SJ; Porto, GBF; Vandergrift, WA; Varma, AK | 1 |
| Mitamura, K; Miyake, K; Nishiyama, Y; Norikane, T; Yamamoto, Y | 1 |
| Elkabets, M; Kong, D; Li, X; Liu, H; Liu, Y; Peng, X; Wang, R; Wang, W; Zhang, S; Zhao, B; Zhong, Y | 1 |
| Jung, SY; Lee, JH; Yoo, K; Yun, HH | 1 |
| Allemanni, G; Banelli, B; Daga, A; Forlani, A; Marubbi, D; Pistillo, MP; Profumo, A; Romani, M | 1 |
| Dong, S; Guo, G; Huang, Q; Li, R; Liu, Y; Lu, J; Nan, Y; Yu, K; Zhang, Z; Zhong, Y; Zhu, L | 1 |
| Arkenau, HT; Auger, KR; Blagden, S; Brown, NF; Cox, D; Fleming, RA; Lenox, L; Lewis, Y; Mulholland, P; Plisson, C; Saleem, A; Searle, G; Singh, R; Tolson, J; Williams, M; Yan, L; Zhang, J | 1 |
| Agar, NYR; Alexander, BM; Basu, SS; Batchelor, TT; Beroukhim, R; Brown, LE; Chang, SM; Chi, AS; Cloughesy, TF; Colman, H; de Groot, JF; DeAngelis, LM; Dunn, IF; Gaffey, SC; Gilbert, MR; Haidar, S; Heath, JR; Horky, LL; Huse, JT; Kim, J; Koul, D; Kuhn, JG; Lee, EQ; Ligon, AH; Ligon, KL; Martinez-Ledesma, JE; McCluskey, CS; Mellinghoff, IK; Nayak, L; Omuro, AM; Park, MA; Pelton, K; Prados, MD; Ramkissoon, S; Reardon, DA; Rinne, ML; Roberts, TM; Touat, M; Wei, W; Wen, PY; Wu, S; Young, GS; Yung, WKA; Zhao, JJ | 1 |
| Ishii, K; Murayama, S; Sengoku, R; Tago, T; Toyohara, J | 1 |
| Beroukhim, R; Buonamici, S; Chung, J; Dabral, SK; Dorsch, M; Filbin, MG; Franchetti, Y; Kelleher, JF; Kung, AL; Ligon, KL; Pak, E; Pazyra-Murphy, MF; Ramkissoon, S; Redjal, N; Segal, RA; Shulman, DS; Sun, Y; Tabak, B; Theisen, MA; Wang, Q; Zhao, J | 1 |
| Dicker, AP; Feo, N; Lawrence, YR; Leiby, B; Liu, Y; Rice, B; Wachsberger, PR | 1 |
| Foster, KA; Jane, EP; Morales, A; Pollack, IF; Premkumar, DR | 1 |
| Ajamie, RT; De Dios, A; Gelbert, LM; Kulanthaivel, P; Raub, TJ; Sanchez-Martinez, C; Sawada, GA; Shannon, HE; Staton, BA; Wishart, GN | 1 |
| Butowski, N; Cloughesy, TF; Colman, H; De Groot, JF; Haidar, S; Hsu, HH; Huse, J; Ligon, KL; Marimuthu, A; Molinaro, AM; Nayak, L; Nolop, KB; Omuro, AM; Perry, A; Phillips, J; Prados, M; Wen, PY; West, BL | 1 |
| Behera, P; Chiocca, EA; Cho, CF; Lawler, SE; Nowicki, MO; Speranza, MC | 1 |
| Bai, X; Heppner, F; Korsing, S; Krementeskaia, I; Nieminen, M; Onken, J; Radke, J; Torka, R; Ullrich, A; Vajkoczy, P | 1 |
| Enger, PØ; Førde, HE; Goplen, D; Leiss, L; Miletic, H; Netland, IA; Rahman, MA; Skeie, BS; Sleire, L | 1 |
| Chang, J; Qiu, Z; Wang, G; Yue, S | 1 |
| Behrmann, CA; Ennis, KN; Feng, X; Jiang, TT; Kofuji, S; Liu, H; Niu, L; Plas, DR; Sarma, P; Sasaki, AT; Stratton, Y; Thomas, HE; Yoon, SO | 1 |
8 trial(s) available for alpha-aminopyridine and Astrocytoma, Grade IV
| Article | Year |
|---|---|
Phase I/II study of bevacizumab with BKM120, an oral PI3K inhibitor, in patients with refractory solid tumors (phase I) and relapsed/refractory glioblastoma (phase II).
Topics: Adult; Aged; Aged, 80 and over; Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Glioblastoma; Humans; Male; Maximum Tolerated Dose; Middle Aged; Morpholines; Neoplasm Recurrence, Local; Neoplasms; Phosphatidylinositol 3-Kinases; Prognosis; Salvage Therapy; Survival Rate | 2019 |
Tumor pharmacokinetics and pharmacodynamics of the CDK4/6 inhibitor ribociclib in patients with recurrent glioblastoma.
Topics: Adult; Aged, 80 and over; Aminopyridines; Biomarkers, Tumor; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Follow-Up Studies; Gene Expression Regulation, Neoplastic; Glioblastoma; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Purines; Survival Rate; Tissue Distribution | 2019 |
A Phase Ib/II, open-label, multicenter study of INC280 (capmatinib) alone and in combination with buparlisib (BKM120) in adult patients with recurrent glioblastoma.
Topics: Adult; Aged; Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Brain Neoplasms; Female; Follow-Up Studies; Glioblastoma; Humans; Imidazoles; Male; Maximum Tolerated Dose; Middle Aged; Morpholines; Neoplasm Recurrence, Local; Prognosis; Proto-Oncogene Proteins c-met; PTEN Phosphohydrolase; Tissue Distribution; Triazines | 2020 |
Phase I, open-label, multicentre study of buparlisib in combination with temozolomide or with concomitant radiation therapy and temozolomide in patients with newly diagnosed glioblastoma.
Topics: Adult; Aged; Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Female; Glioblastoma; Humans; Male; Middle Aged; Morpholines; Phosphatidylinositol 3-Kinases; Temozolomide | 2020 |
Buparlisib plus carboplatin or lomustine in patients with recurrent glioblastoma: a phase Ib/II, open-label, multicentre, randomised study.
Topics: Aged; Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Bayes Theorem; Carboplatin; Female; Glioblastoma; Humans; Lomustine; Male; Middle Aged; Morpholines; Phosphatidylinositol 3-Kinases; Recurrence | 2020 |
A study of the focal adhesion kinase inhibitor GSK2256098 in patients with recurrent glioblastoma with evaluation of tumor penetration of [11C]GSK2256098.
Topics: Adolescent; Adult; Aged; Aminopyridines; Carbon Radioisotopes; Cohort Studies; Female; Focal Adhesion Protein-Tyrosine Kinases; Follow-Up Studies; Glioblastoma; Humans; Hydroxamic Acids; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Tissue Distribution; Young Adult | 2018 |
Buparlisib in Patients With Recurrent Glioblastoma Harboring Phosphatidylinositol 3-Kinase Pathway Activation: An Open-Label, Multicenter, Multi-Arm, Phase II Trial.
Topics: Adult; Aged; Aged, 80 and over; Aminopyridines; Antineoplastic Agents; Brain Neoplasms; Chemotherapy, Adjuvant; Disease Progression; Enzyme Activation; Female; Glioblastoma; Humans; Male; Middle Aged; Morpholines; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Phosphatidylinositol 3-Kinase; Phosphoinositide-3 Kinase Inhibitors; Progression-Free Survival; Time Factors | 2019 |
Orally administered colony stimulating factor 1 receptor inhibitor PLX3397 in recurrent glioblastoma: an Ivy Foundation Early Phase Clinical Trials Consortium phase II study.
Topics: Administration, Oral; Aminopyridines; Biomarkers, Tumor; Blood-Brain Barrier; Brain Neoplasms; Cohort Studies; Female; Follow-Up Studies; Glioblastoma; Humans; Immunoenzyme Techniques; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Pyrroles; Receptors, Granulocyte-Macrophage Colony-Stimulating Factor; Tissue Distribution; Tumor Burden | 2016 |
16 other study(ies) available for alpha-aminopyridine and Astrocytoma, Grade IV
| Article | Year |
|---|---|
MGMT-inhibitor in combination with TGF-βRI inhibitor or CDK 4/6 inhibitor increases temozolomide sensitivity in temozolomide-resistant glioblastoma cells.
Topics: Aminopyridines; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Astrocytes; Benzimidazoles; Brain Neoplasms; Cell Cycle; Cell Survival; Cells, Cultured; Cyclin D; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; DNA Modification Methylases; DNA Repair Enzymes; Drug Resistance, Neoplasm; G1 Phase Cell Cycle Checkpoints; Glioblastoma; Guanine; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Neurons; Phosphatidylinositol 3-Kinases; Pyrazoles; Quinolines; Receptor, Transforming Growth Factor-beta Type I; Smad Proteins; Temozolomide; Tumor Suppressor Proteins | 2021 |
Increased Uptake of 18F-THK5351 in Glioblastoma But Not in Primary Central Nervous System Lymphoma.
Topics: Aminopyridines; Central Nervous System; Glioblastoma; Humans; Lymphoma, Non-Hodgkin; Methionine; Positron-Emission Tomography; Quinolines | 2021 |
BKM120 sensitizes glioblastoma to the PARP inhibitor rucaparib by suppressing homologous recombination repair.
Topics: Aminopyridines; Animals; Female; Glioblastoma; Humans; Indoles; Mice; Morpholines; Poly(ADP-ribose) Polymerase Inhibitors; Recombinational DNA Repair; Zebrafish | 2021 |
KRIBB11 Induces Apoptosis in A172 Glioblastoma Cells via MULE-Dependent Degradation of MCL-1.
Topics: Aminopyridines; Apoptosis; Apoptosis Regulatory Proteins; Cell Line, Tumor; Glioblastoma; Glioma; Humans; Indazoles; Myeloid Cell Leukemia Sequence 1 Protein; Proto-Oncogene Proteins c-bcl-2; Tumor Suppressor Proteins; Ubiquitin; Ubiquitin-Protein Ligases | 2021 |
Small molecules targeting histone demethylase genes (KDMs) inhibit growth of temozolomide-resistant glioblastoma cells.
Topics: Aminopyridines; Animals; Blood-Brain Barrier; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dacarbazine; Drug Resistance, Neoplasm; Drug Synergism; Enzyme Inhibitors; Gene Expression Regulation, Neoplastic; Glioblastoma; Histone Demethylases; Humans; Hydrazones; Mice; Phosphorylation; Proto-Oncogene Proteins c-akt; Retinoblastoma-Binding Protein 2; Small Molecule Libraries; Temozolomide; Xenograft Model Antitumor Assays | 2017 |
Amlexanox, a selective inhibitor of IKBKE, generates anti-tumoral effects by disrupting the Hippo pathway in human glioblastoma cell lines.
Topics: Aminopyridines; Animals; Antineoplastic Agents; Apoptosis; Brain Neoplasms; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Female; Gene Expression Regulation, Neoplastic; Glioblastoma; Hippo Signaling Pathway; Humans; I-kappa B Kinase; Mice; Mice, Nude; Neoplasm Invasiveness; Protein Serine-Threonine Kinases; Proteolysis; Signal Transduction; Tumor Suppressor Proteins; Xenograft Model Antitumor Assays | 2017 |
Monoamine Oxidase B Binding of 18F-THK5351 to Visualize Glioblastoma and Associated Gliosis: An Autopsy-Confirmed Case.
Topics: Aged, 80 and over; Aminopyridines; Brain Neoplasms; Female; Glioblastoma; Humans; Monoamine Oxidase; Positron-Emission Tomography; Protein Binding; Quinolines; Radiopharmaceuticals | 2019 |
Coordinate activation of Shh and PI3K signaling in PTEN-deficient glioblastoma: new therapeutic opportunities.
Topics: Aminopyridines; Animals; Biphenyl Compounds; Brain Neoplasms; Cell Line, Tumor; Enzyme Inhibitors; Glioblastoma; Hedgehog Proteins; Humans; Mice; Mice, Nude; Morpholines; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; PTEN Phosphohydrolase; Pyridines; Ribosomal Protein S6 Kinases; Signal Transduction; Xenograft Model Antitumor Assays | 2013 |
Hsp90 inhibition enhances PI-3 kinase inhibition and radiosensitivity in glioblastoma.
Topics: Aminopyridines; Animals; Apoptosis; Blotting, Western; Brain Neoplasms; Cell Proliferation; Flow Cytometry; Gene Expression Regulation, Neoplastic; Glioblastoma; HSP90 Heat-Shock Proteins; Humans; Mice; Mice, Nude; Morpholines; Phosphatidylinositol 3-Kinase; Phosphoinositide-3 Kinase Inhibitors; Radiation Tolerance; Radiation-Sensitizing Agents; Tumor Cells, Cultured | 2014 |
Inhibition of phosphatidylinositol 3-kinase/AKT signaling by NVP-BKM120 promotes ABT-737-induced toxicity in a caspase-dependent manner through mitochondrial dysfunction and DNA damage response in established and primary cultured glioblastoma cells.
Topics: Aminopyridines; Antineoplastic Agents; Apoptosis Inducing Factor; Apoptosis Regulatory Proteins; bcl-2 Homologous Antagonist-Killer Protein; bcl-2-Associated X Protein; Bcl-2-Like Protein 11; Biphenyl Compounds; Caspase 3; Caspase 8; Caspases; Cell Death; Cell Line, Tumor; Chromosome Segregation; Cytochromes c; DNA Damage; Drug Synergism; Glioblastoma; Humans; Intracellular Signaling Peptides and Proteins; Membrane Potential, Mitochondrial; Membrane Proteins; Mitochondria; Mitochondrial Proteins; Morpholines; Nitrophenols; Phosphoinositide-3 Kinase Inhibitors; Piperazines; Poly(ADP-ribose) Polymerases; Primary Cell Culture; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-bcl-2; Signal Transduction; Sulfonamides | 2014 |
Brain Exposure of Two Selective Dual CDK4 and CDK6 Inhibitors and the Antitumor Activity of CDK4 and CDK6 Inhibition in Combination with Temozolomide in an Intracranial Glioblastoma Xenograft.
Topics: Aminopyridines; Animals; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Brain; Brain Neoplasms; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Dacarbazine; Dogs; Female; Glioblastoma; Madin Darby Canine Kidney Cells; Male; Mice; Piperazines; Protein Kinase Inhibitors; Pyridines; Rats; Temozolomide; Xenograft Model Antitumor Assays | 2015 |
BKM-120 (Buparlisib): A Phosphatidyl-Inositol-3 Kinase Inhibitor with Anti-Invasive Properties in Glioblastoma.
Topics: Aminopyridines; Animals; Blood-Brain Barrier; Brain Neoplasms; Cell Adhesion; Cell Culture Techniques; Cell Line, Tumor; Cell Movement; Cell Proliferation; Enzyme Inhibitors; Glioblastoma; Humans; Mice; Mice, Nude; Microtubules; Morpholines; Neoplasm Invasiveness; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Spheroids, Cellular; Transplantation, Heterologous; Vimentin | 2016 |
Inhibiting receptor tyrosine kinase AXL with small molecule inhibitor BMS-777607 reduces glioblastoma growth, migration, and invasion in vitro and in vivo.
Topics: Aminopyridines; Angiogenesis Inhibitors; Animals; Apoptosis; Axl Receptor Tyrosine Kinase; Blotting, Western; Brain Neoplasms; Cell Line; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Glioblastoma; Humans; Immunohistochemistry; Mice, Nude; Microscopy, Fluorescence; Neoplasm Invasiveness; Phosphorylation; Proto-Oncogene Proteins; Pyridones; Receptor Protein-Tyrosine Kinases; Tumor Burden; Xenograft Model Antitumor Assays | 2016 |
Treatment with the PI3K inhibitor buparlisib (NVP-BKM120) suppresses the growth of established patient-derived GBM xenografts and prolongs survival in nude rats.
Topics: Aminopyridines; Animals; Antineoplastic Agents; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Glioblastoma; Humans; Morpholines; Phosphoinositide-3 Kinase Inhibitors; Phosphorylation; Proto-Oncogene Proteins c-akt; Rats, Nude; Survival Analysis; Xenograft Model Antitumor Assays | 2016 |
[Phosphatidylinositide 3-kinase inhibitor BKM120 suppresses proliferation and promotes apoptosis of U251 glioblastoma cells].
Topics: Aminopyridines; Apoptosis; bcl-2-Associated X Protein; Blotting, Western; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Flow Cytometry; Glioblastoma; Humans; Morpholines; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Proto-Oncogene Proteins c-bcl-2 | 2016 |
Pharmacologic Targeting of S6K1 in PTEN-Deficient Neoplasia.
Topics: Aminopyridines; Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Gene Knockdown Techniques; Glioblastoma; Heterocyclic Compounds, 4 or More Rings; Humans; Leukemia, T-Cell; Mice; Neoplasms; Phosphorylation; PTEN Phosphohydrolase; Pyridones; Receptor Protein-Tyrosine Kinases; Ribosomal Protein S6 Kinases, 70-kDa; Signal Transduction; TOR Serine-Threonine Kinases | 2017 |